← FDA DRUG APPROVALS

FDA ANDA · ANDA040594

MERCAPTOPURINE

Sponsor: MYLAN

APPLICATION
ANDA040594
TYPE
ANDA
ORIGINAL APPROVAL
2005-07-01
LATEST ACTION
2025-02-14
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

MERCAPTOPURINEDiscontinued
MERCAPTOPURINE 50MG · TABLET · ORAL

Approval history

2025-02-14Labeling · Supplement 15 · standardAP
2022-01-24Labeling · Supplement 13 · standardAP
2021-01-29Labeling · Supplement 12 · standardAP
2018-12-10Labeling · Supplement 10 · standardAP
2013-05-14Labeling · Supplement 6 · standardAP
2005-07-01OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →